Patients should be monitored closely to ensure that the lowest approved dose of Epoetin alfa is used to provide adequate control of anaemia and of the symptoms of anaemia.
Patsiente tuleb hoolikalt jälgida veendumaks, et neil esineva aneemia ja aneemia sümptomite adekvaatseks raviks kasutatakse madalaimat vajalikku alfaepoetiini annust.